ANALYST-DOWNGRADE filed
HSBC double-downgraded Thermo Fisher Scientific (TMO) from Buy to Hold on June 3, slashing its price target by 19.4% to $540 from $670. The call is a sharp contrarian move against a consensus that remains 85% Buy-rated (29 of 34 analysts at Buy or Strong Buy). TMO currently trades at $482.08, implying a 13.4% upside to the new HSBC target but a 12% discount to the consensus mean of $611.56. HSBC's accuracy on TMO is 67% (2 of 3 calls) with a negative average return of -0.4%, ranking it below top-tier firms like Baird (83% on 6 calls) and Barclays (80% on 10 calls). The downgrade is the only negative analyst action in the past 30 days, with zero upgrades and one downgrade. EPS revisions are mixed: the current quarter saw 12 downward revisions in 30 days, while the next quarter (+1q) saw 14 upward revisions, suggesting near-term headwinds but a potential rebound. Insider selling is present but not alarming, two sales totaling ~$1M in March-April, with no buys. Institutional buying is strong, with FMR LLC adding 29% and Bank of America adding 34.9%. The bottom line: HSBC's downgrade is a minority view from a mediocre-accuracy firm, but the large PT cut and the double-downgrade signal warrant caution against the overwhelmingly bullish consensus.